Akeso, Inc.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and nec… Read more
Akeso, Inc. (AKESF) - Net Assets
Latest net assets as of June 2025: $6.36 Billion USD
Based on the latest financial reports, Akeso, Inc. (AKESF) has net assets worth $6.36 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.29 Billion) and total liabilities ($6.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.36 Billion |
| % of Total Assets | 47.84% |
| Annual Growth Rate | 18.28% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 40.23 |
Akeso, Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Akeso, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Akeso, Inc. (2020–2024)
The table below shows the annual net assets of Akeso, Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.75 Billion | +49.45% |
| 2023-12-31 | $4.52 Billion | +77.35% |
| 2022-12-31 | $2.55 Billion | -22.32% |
| 2021-12-31 | $3.28 Billion | -4.93% |
| 2020-12-31 | $3.45 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Akeso, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 240427900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.22 Billion | 135.28% |
| Total Equity | $6.81 Billion | 100.00% |
Akeso, Inc. Competitors by Market Cap
The table below lists competitors of Akeso, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AVMPF
PINK:AVMPF
|
$7.28 Billion |
|
Gulf Energy Development Public Company Limited
BK:GULF
|
$7.28 Billion |
|
A.O. Smith Corp.
LSE:0L7A
|
$7.28 Billion |
|
EPAM Systems Inc
NYSE:EPAM
|
$7.28 Billion |
|
AtkinsRéalis Group Inc
PINK:SNCAF
|
$7.27 Billion |
|
Orkla ASA
PINK:ORKLF
|
$7.25 Billion |
|
Alchip Technologies Ltd
TW:3661
|
$7.24 Billion |
|
Armstrong World Industries Inc
NYSE:AWI
|
$7.24 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akeso, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,692,339,000 to 6,813,953,000, a change of 2,121,614,000 (45.2%).
- Net loss of 514,515,000 reduced equity.
- New share issuances of 2,851,133,000 increased equity.
- Other factors decreased equity by 215,004,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-514.51 Million | -7.55% |
| Share Issuances | $2.85 Billion | +41.84% |
| Other Changes | $-215.00 Million | -3.16% |
| Total Change | $- | 45.21% |
Book Value vs Market Value Analysis
This analysis compares Akeso, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.56x to 1.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $4.05 | $10.34 | x |
| 2021-12-31 | $3.87 | $10.34 | x |
| 2022-12-31 | $3.13 | $10.34 | x |
| 2023-12-31 | $5.58 | $10.34 | x |
| 2024-12-31 | $7.59 | $10.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akeso, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.22%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.87x
- Recent ROE (-7.55%) is above the historical average (-15.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -36.95% | 0.00% | 0.00x | 1.21x | $-1.50 Billion |
| 2021 | -33.97% | -476.42% | 0.05x | 1.52x | $-1.39 Billion |
| 2022 | -44.33% | -139.48% | 0.15x | 2.09x | $-1.43 Billion |
| 2023 | 43.23% | 44.81% | 0.49x | 1.96x | $1.56 Billion |
| 2024 | -7.55% | -24.22% | 0.17x | 1.87x | $-1.20 Billion |
Industry Comparison
This section compares Akeso, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akeso, Inc. (AKESF) | $6.36 Billion | -36.95% | 1.09x | $7.27 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |